Our Technology
Capsidvax develops novel nanoparticles and virus-like particles (VLPs) using an innovative cell-based manufacturing platform that generates precisely engineered macromolecular structures for a wide range of applications. These include highly immunogenic, non-infectious mono- and multivalent vaccines, cancer immunotherapeutics, and nanovehicles for targeted therapeutic delivery.
VLP Platforms
Custom virus-like particles engineered to enhance vaccine efficacy and immune response.
Drug Delivery
Targeted nanoparticle systems crafted to deliver therapeutics precisely where needed.
Innovation
Engineering nanoparticles for next-gen medical breakthroughs
Nanoparticles and virus-like particles are biological structures that resemble the organization and conformation of native viral capsids or envelopes, yet remain noninfectious because they lack viral genetic material. These properties make them safer and more cost-effective alternatives for vaccine development, while also enabling their use as versatile carriers for the delivery of therapeutics, immunotherapeutics, and other bioactive molecules across a broad range of applications.
